Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Chroma Medicine

Main focus: Epigenetic engineering

Company stage: Pre-clinical

Diseases: Undisclosed

(Epi) Genome-editing tool: Undisclosed

Funding stage: Private

Location: Cambridge, MA, USA

Website: https://chromamedicine.com/

Chroma Medicine is a start-up company focused on engineering the epigenome. The company develops epigenetic editors that are able to either silence or activate genes by targeted methylation and demethylation of DNA. Recently, the company raised $125M in a Series A funding round.

Chroma Medicine

Your Latest CMN News

CMN Weekly (26 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

Company: Chroma Medicine

Search CRISPR Medicine